TABLE 3.
Edoxaban interruption and associated outcomes
| No edoxaban interruption | # of subjects | MB | MB & CRNMB | All bleeding | Death—anycause | ACS | ATE & cardiac deaths | Clinically relevant events (MB + CRNMB and thrombosis) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 345 | 0 | 3 (0.9%) | 14 (4.1%) | 1 (0.3%) | 0 | 0 | 3 (0.9%) | ||||
| Preprocedural interruption: N = 781, mean 1.9 ± 1.08 days. Median 2.0 days, Q1 1.0, Q3 2.0, range 1‐6 | |||||||||||
| None | 374 | 0 | 3 (0.8%) | 17 (4.5%) | 2 (0.5%) | 0 | 0 | 3 (0.8%) | |||
| 1 day | 358 | 2 (0.6%) | 4 (1.1%) | 9 (2.5%) | 1 (0.3%) | 0 | 1 (0.3%) | 5 (1.4%) | |||
| 2 days | 251 | 1 (0.4%) | 3 (1.2%) | 8 (3.2%) | 0 | 0 | 2 (0.8%) | 5 (2.0%) | |||
| 3 days | 111 | 2 (1.8%) | 2 (1.8%) | 11 (9.9%) | 0 | 1 (0.9%) | 0 | 3 (2.7%) | |||
| ≥4 days | 61 | 0 | 1 (1. 6%) | 4 (6.6%) | 2 (3.3%) | 3 (4.9%) | 4 (6.6%) | ||||
| Postprocedural interruption: N = 308, mean 6.6 ± 8.24 days. Median 3.0 days, Q1 1.0, Q3 8.0, range 1‐29 | |||||||||||
| None | 847 | 1 (0.1%) | 4 (0.5%) | 24 (2.8%) | 1 (0.1%) | 0 | 1 (0.1%) | 5 (0.6%) | |||
| 1 day | 112 | 0 | 2 (1.8%) | 6 (5.4%) | 0 | 1 (0.9%) | 0 | 3 (2.7%) | |||
| 2 days | 36 | 0 | 1 (2.8%) | 3 (8.3%) | 2 (5.6%) | 0 | 1 (2.8%) | 2 (5.6%) | |||
| 3 days | 22 | 0 | 0 | 1 (4.5%) | 0 | 0 | 0 | 0 | |||
| ≥4 days | 138 | 4 (2.9%) | 6 (4.3%) | 15 (10.9%) | 2 (1.4%) | 0 | 4 (2.9%) | 10 (7.2%) | |||
Abbreviations: ACS, acute coronary syndrome; ATE, acute thromboembolic event; CRNMB, clinically relevant non‐major bleeding; CV, cardiovascular; EHRA, European Heart Rhythm Association; MB, major bleeding.